An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

Fortunately, recent studies have found lung function decline to be decreasing, yet patients are still experiencing frequent exacerbations, which means that current interventions have not been enough.

Around 1.5 million patients succumb to the disease caused by the bacterium Mycobacterium tuberculosis (Mtb). The novel ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

In a rapidly evolving digital landscape, the healthcare industry is experiencing a seismic shift, driven by the integration of cutting-edge technologies. These advancements are unlocking unprecedented ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including ...

Dr. Abdelrhman Maher Abo-Zed is a triple board-certified physician in internal medicine, pulmonary, and critical care ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Every year, 10 million people contract tuberculosis (TB), a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), and approximately 1.5 million patients succumb to the disease. Treatment ...

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.